Compare · CNC vs EXAS
CNC vs EXAS
Side-by-side comparison of Centene Corporation (CNC) and Exact Sciences Corporation (EXAS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and EXAS operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $30.78B, about 2.5x EXAS ($12.19B).
- Over the past year, CNC is up 11.9% and EXAS is up 92.1% - EXAS leads by 80.3 points.
- CNC has hit the wire 6 times in the past 4 weeks while EXAS has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Centene Corporation
- Exact Sciences Corporation
- Price
- $62.31-0.59%
- $104.94+1.02%
- Market cap
- $30.78B
- $12.19B
- 1M return
- +12.64%
- +1.60%
- 1Y return
- +11.86%
- +92.13%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2001
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 25
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Latest CNC
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Five Stars: Health Net Recognized by USA TODAY for Customer Service; Only California-Based Health Insurer Recognized with Highest Rating
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Centene upgraded by Deutsche Bank with a new price target
- New insider Finke Daniel P claimed ownership of 228,127 shares (SEC Form 3)
- New insider Carson Michael A claimed ownership of 123,707 shares (SEC Form 3)
- Centene Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update
- Director Tanji Kenneth was granted 3,992 shares, increasing direct ownership by 50% to 11,909 units (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 3,992 shares, increasing direct ownership by 19% to 24,748 units (SEC Form 4)
- Director Ford Monte E was granted 3,992 shares, increasing direct ownership by 37% to 14,827 units (SEC Form 4)
Latest EXAS
- SEC Form 15-12G filed by Exact Sciences Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Exact Sciences Corporation
- SEC Form POSASR filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation
- SEC Form S-8 POS filed by Exact Sciences Corporation